Difference between revisions of "Programmed death-ligand 1"
Jump to navigation
Jump to search
| Line 5: | Line 5: | ||
==General== | ==General== | ||
*[[IHC]] testing using a PD-L1 antibody (demonstrating positive tumour cells) predicts response to anti-PD-L1 drugs.<ref name=pmid26970723/> | *[[IHC]] testing using a PD-L1 antibody (demonstrating positive tumour cells) predicts response to anti-PD-L1 drugs.<ref name=pmid26970723/> | ||
==Background== | |||
Cytotoxic T cell activation is driven by two sets of receptors:<ref>{{Cite journal | last1 = Ribas | first1 = A. | title = Tumor immunotherapy directed at PD-1. | journal = N Engl J Med | volume = 366 | issue = 26 | pages = 2517-9 | month = Jun | year = 2012 | doi = 10.1056/NEJMe1205943 | PMID = 22658126 }}</ref> | |||
{| class="wikitable sortable" | |||
! Function | |||
! Tumour cell | |||
! T cell | |||
|- | |||
| Antigen presentation | |||
| MHC | |||
| TCR | |||
|- | |||
| Inhibition | |||
| [[PD-1]] | |||
| PD-L1 (CD274), PD-L2 (CD273) | |||
|} | |||
==Prognosis== | ==Prognosis== | ||